Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Diltiazem (hydrochloride)

Diltiazem hydrochloride is a Ca2+ influx inhibitor (slow channel blocker or calcium antagonist) .

Product Specifications

CAS Number

[33286-22-5]

Product Name Alternative

CRD-401

UNSPSC

12352005

Hazard Statement

H302+H312+H332, H319, H350, H360

Target

Calcium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

COVID-19-anti-virus

Field of Research

Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/diltiazem-hydrochloride.html

Purity

99.83

Solubility

H2O : 33.33 mg/mL (ultrasonic)

Smiles

CN(C)CCN1C2=CC=CC=C2S[C@@H](C3=CC=C(OC)C=C3)[C@@H](OC(C)=O)C1=O.Cl

Molecular Formula

C22H27ClN2O4S

Molecular Weight

450.98

Precautions

H302+H312+H332, H319, H350, H360

References & Citations

[1]Kraus RL, et al. Molecular mechanism of diltiazem interaction with L-type Ca2+ channels. J Biol Chem. 1998 Oct 16;273 (42) :27205-12.|[2]van Breemen C, et al. The mechanism of inhibitory action of diltiazem on vascular smooth muscle contractility. J Pharmacol Exp Ther. 1981 Aug;218 (2) :459-63.|[3]Chiesi M, et al. Stereospecific action of diltiazem on the mitochondrial Na-Ca exchange system and on sarcolemmal Ca-channels. Biochem Pharmacol. 1987 Sep 1;36 (17) :2735-40.|[4]Freitas F, et al. Cardiac microvascular rarefaction in hyperthyroid rats is reversed by losartan, diltiazem, and propranolol. Fundam Clin Pharmacol. 2015 Feb;29 (1) :31-40.|[5]Sato M, et al. Hypotensive effects of diltiazem hydrochloride in the normotensive, spontaneously hypertensive and renal hypertensive rats (author's transl) . Nihon Yakurigaku Zasshi. 1979 Mar;75 (2) :99-106.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

L-type calcium channel

Citation 01

MedRxiv. 2025 May 21.|Pharmacol Res Perspect. 2020 Apr;8 (2) :e00575.|Vet Sci. 2025 Sep 5;12 (9) :864.|Virology. 2020 Jan 2;539:38-48.|ACS Environ Au. 2025 Aug 8.|Anal Chem. 2025 Jun 3;97 (21) :11099-11109.|J Cardiovasc Transl Res. 2023 Aug;16 (4) :758-767.|Nat Commun. 2024 Jun 19;15 (1) :5230.|Pharmacol Res Perspect. 2021 Oct;9 (5) :e00879.

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

RGL3 (NM_001035223) Human Over-expression Lysate
LS057139-100ug 100 µg

RGL3 (NM_001035223) Human Over-expression Lysate

Ask
View Details
Recombinant Human Tenascin (TNC), partial
MBS1265425-01 0.02 mg (E-Coli)

Recombinant Human Tenascin (TNC), partial

Ask
View Details
Recombinant Human Tenascin (TNC), partial
MBS1265425-02 0.1 mg (E-Coli)

Recombinant Human Tenascin (TNC), partial

Ask
View Details
Recombinant Human Tenascin (TNC), partial
MBS1265425-03 1 mg (E-Coli)

Recombinant Human Tenascin (TNC), partial

Ask
View Details
Recombinant Human Tenascin (TNC), partial
MBS1265425-04 5x 1 mg (E-Coli)

Recombinant Human Tenascin (TNC), partial

Ask
View Details
HIV-1 (Human Immunodeficiency Virus-1) (FITC)
H6001-21-FITC 100 µL

HIV-1 (Human Immunodeficiency Virus-1) (FITC)

Ask
View Details